spec sheet12 rows
P7C3 is an investigational neuroprotective compound of the aminopropyl carbazole class, studied only in laboratory and animal research. It is proposed to work by boosting cellular NAD+ through activation of the enzyme NAMPT, which helps preserve the survival of newly formed and stressed neurons. In animal models it has shown protective effects in conditions such as stroke, traumatic brain injury, and neurodegeneration, but it is not an approved medicine.
- Strong neurogenesis in animals
- Neuroprotection after injury
- Supports NAD+ metabolism
- Antidepressant-like effects in models
Overview
P7C3 is the founding member of a family of aminopropyl carbazole compounds developed as experimental neuroprotective and pro-neurogenic agents [3]. It was identified through screening for small molecules that protect newborn neurons in the hippocampus, and later medicinal chemistry produced more active analogues, among them P7C3-A20 [1]. The compounds serve as research tools rather than approved drugs, and their study spans a range of nervous-system injury and disease models.
Mechanistic work indicates that the P7C3 chemotype protects cells by supporting the NAD+ salvage pathway; the molecules enhance the activity of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of that pathway, thereby helping to maintain the cellular cofactor NAD+ and to limit stress-induced cell death [3]. In rodent studies, P7C3-A20 reduced tissue damage and improved recovery after ischemic stroke [1], and P7C3 agents have been reported to lessen injury and preserve function in models of traumatic brain injury [2]. Additional research has implicated signaling through the glucagon-like peptide-1 receptor and inhibition of GSK-3 in the neurogenesis-promoting effects seen after experimental brain ischemia [4].
Because P7C3 remains an experimental agent, it has no approved therapeutic use, no regulatory marketing authorization, and no standardized clinical formulation; it exists chiefly as a laboratory chemical used in preclinical neuroscience [2]. Interest in the class stems from the breadth of models in which it appears protective, including paradigms relevant to neurodegeneration, nerve injury, and mood-related behavior, although the findings to date come from cell and animal systems rather than established human trials [3].
Mechanism
The neuroprotective activity of P7C3 compounds is attributed mainly to their support of nicotinamide adenine dinucleotide () metabolism [3]. By increasing the activity of NAMPT, the enzyme that limits the rate of regeneration from nicotinamide, the molecules help sustain intracellular NAD+ levels, which supports energy production and the biochemical defenses that keep stressed or newly generated neurons from undergoing programmed cell death [3]. This preservation of vulnerable neurons underlies the improved cell survival and functional recovery observed in animal models of stroke and traumatic brain injury [1][2]. Separate work suggests that, in some settings, P7C3 also engages glucagon-like -1 receptor signaling and downstream inhibition of GSK-3 to promote the formation of new neurons after brain injury [4].
⚠️ Two qualifications belong with the NAMPT account above. No binding or potency constant at that enzyme has ever been published for any compound in this series, in the founding paper or in the fifteen years since; the supporting evidence was competition against a chemical probe and activation of recombinant enzyme at a single high concentration. The two NAMPT activators that have been structurally characterised bind a site called the rear channel [6], and no such binding has been shown here. The originating laboratory now writes that these compounds stabilise NAD rather than that they activate the enzyme, and the NAD effect itself appears only in depleted cells; the founding work reported no change in untreated ones.
⚠️ The only fully independent laboratory to test P7C3-A20 in culture found no protection against degeneration in three separate primary neuron systems, and reported concentration-dependent neurotoxicity [5]. That result has never been reconciled with the animal literature, and it is the reason this series should be read as unsettled rather than merely early.
⚠️ The -1 receptor mechanism described above belongs to this prototype specifically. Its own source paper states that P7C3-A20 and P7C3-S243 do not engage that pathway, so it should not be carried across to them.
receptor fingerprint
Hippocampal promotes
functionsupports
Neuronal apoptosisinhibits
NAMPT enzymeClaimed activator; no constant ever measured
Dosingtypical ranges, not medical advice
interested in protocols and clinical dosages? make an account to see them! ^_^
Safetyrisks and cautions, not medical advice
There is no established human safety profile; everything known comes from animal studies, where it has appeared relatively well tolerated. Because it is an unapproved research chemical, purity, dosing, and long-term risks are all unknowns. Self-experimentation is strongly discouraged.
Resources
This entry is here for reference.
Research
- 2011first citedDevelopment of proneurogenic, neuroprotective small molecules
- 2023most recentSynthesis, Optimization, and Structure-Activity Relationships of Nicotinamide Phosphoribosyltra…
- 1.Neuroprotective Efficacy of an Aminopropyl Carbazole Derivative P7C3-A20 in Ischemic Stroke
- 2.Neurotherapeutic capacity of P7C3 agents for the treatment of Traumatic Brain Injury
- 3.P7C3 neuroprotective chemicals function by activating the rate-limiting enzyme in NAD salvage
- 4.GSK-3 inhibition through GLP-1R allosteric activation mediates the neurogenesis promoting effect of P7C3 after cerebral ischemic/reperfusional injury in mice
- 5.P7C3-A20 neuroprotection is independent of Wallerian degeneration in primary neuronal culture
- 6.Synthesis, Optimization, and Structure-Activity Relationships of Nicotinamide Phosphoribosyltransferase (NAMPT) Positive Allosteric Modulators (N-PAMs)
- 7.Development of proneurogenic, neuroprotective small molecules
7 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
Can I buy and take P7C3?
It is sold as a research chemical, but there is no human safety data, so taking it is not recommended.
How does it relate to NAD+ boosters like NMN?
It also raises NAD+, but via activating the NAMPT enzyme rather than supplying a precursor.
Is it approved for any disease?
No; it remains a preclinical research compound.
What conditions is it studied for?
Mostly Parkinson's, ALS, traumatic brain injury, and depression in animal models.
Limitations of the evidence
- Not evaluated for safety in humans
- Side-effect profile in people is unknown
- Studied only in laboratory and animal research
- No approved medical use or standardized preparation
- No binding or potency constant at NAMPT has ever been published for any compound in this series
- The only fully independent in-culture test of the series found no protection and concentration-dependent neurotoxicity
- Zero registered clinical trials fifteen years after discovery
- P7C3, P7C3-A20 and P7C3-S243 are distinct compounds and are not interchangeable